Ammar Ali, Hassan Rizvi Syed N, Saghir Tahir, Khan Naveedullah, Akhtar Parveen, Mengal Naeem, Sial Jawaid A, Qamar Nadeem
Adult Cardiology, National Institute of Cardiovascular Diseases, Karachi, PAK.
Interventional Cardiology, National Institute of Cardiovascular Diseases, Karachi, PAK.
Cureus. 2020 Nov 16;12(11):e11497. doi: 10.7759/cureus.11497.
Background The aim of this study was to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) program in a Tertiary care hospital in Karachi, Pakistan. Methodology This study was conducted by interventional cardiology department of the National Institute of Cardiovascular Diseases (NICVD), Karachi from July 2015 to February 2020. All patients of severe aortic stenosis (AS) who underwent TAVI were included. Baseline characteristics, in-hospital course and one-month follow-up data were collected. Results This study included 100 consecutive patients with severe AS undergoing TAVI. Sixty-three (63.0%) patients were males and the mean age was 67.38 ± 10.73 years. Eighty-five (85%) patients were in the New York Heart Association (NYHA) class III-IV. Aortic valve mean gradient was 51.33±10.47 mmHg and 50% of patients had bicuspid aortic valves. Core valve was implanted in 86 (86%) and evolute-R aortic valve was implanted in 14 (14%) patients. TAVI was successfully done in 94% of patients. Post-deployment aortic valve mean gradient was 5.33±4.13 mmHg. Major vascular access site complications were noted in 14% and atrioventricular (AV) blocks were seen in 22% of cases. There was a significant difference in symptoms of patients before and after the procedure. Overall, eight (8%) patients expired during hospital stay. At one-month follow-up, 76% of patients were found to have no limitation of physical activities. Conclusions Results of this study showed that TAVI is a safe procedure in these high-risk patients and is an alternative to surgery for AS patients in the region.
背景 本研究的目的是评估在巴基斯坦卡拉奇一家三级护理医院开展的经导管主动脉瓣植入术(TAVI)项目的安全性和有效性。方法 本研究由卡拉奇国家心血管疾病研究所(NICVD)的介入心脏病学科于2015年7月至2020年2月进行。纳入所有接受TAVI的重度主动脉瓣狭窄(AS)患者。收集基线特征、住院过程和1个月随访数据。结果 本研究纳入了100例连续接受TAVI的重度AS患者。63例(63.0%)为男性,平均年龄为67.38±10.73岁。85例(85%)患者属于纽约心脏协会(NYHA)III-IV级。主动脉瓣平均压差为51.33±10.47 mmHg,50%的患者患有二叶式主动脉瓣。86例(86%)患者植入了Core瓣膜,14例(14%)患者植入了Evolute-R主动脉瓣膜。94%的患者TAVI手术成功完成。术后主动脉瓣平均压差为5.33±4.13 mmHg。14%的患者出现主要血管入路部位并发症,22%的病例出现房室传导阻滞。手术前后患者症状有显著差异。总体而言,8例(8%)患者在住院期间死亡。在1个月随访时,76%的患者被发现无体力活动受限。结论 本研究结果表明,TAVI对于这些高危患者是一种安全的手术方式,并且是该地区AS患者手术治疗的一种替代方法。